Delivering advanced aesthetic dermatology with science, precision, and care. Your skin journey at Akumentis, guided by expertise, trust, and lasting confidence.
Explore More
Location
Contact
Social Media
REVOFIL
Stay Active and Stay Spectacular
A long-lasting peptide complex dermal filler with clinically proven safety — CE2265 certified by CAREGEN CO., LTD.
AKUMENTIS × CAREGEN PARTNERSHIP
REVOFIL Advanced Peptide Dermal Filler Range
Akumentis Healthcare proudly brings the globally trusted aesthetic innovations of Caregen to India with the advanced REVOFIL dermal filler range. Developed by CAREGEN CO., LTD., REVOFIL represents the next generation of peptide-based dermal filler technology designed for modern aesthetic medicine. The formulation combines stabilized Hyaluronic Acid with a proprietary peptide complex to enhance filler durability, skin integration, and natural-looking results.
With clinically validated formulations and CE2265 certification, the REVOFIL portfolio offers both cross-linked designed to support long-lasting and reliable aesthetic outcomes. Through this collaboration, Akumentis Healthcare aims to provide medical professionals with advanced global technologies that elevate treatment quality, improve patient satisfaction, and support the evolving needs of aesthetic practice.
The REVOFIL Product Range
REVOFIL offers a comprehensive suite of CE2265-certified dermal fillers engineered for precision, longevity, and natural-looking results. The range is divided into two core categories — cross-linked each formulated with a proprietary peptide complex to maximize HA stability and duration in the skin.
Cross-Linked Filler
23 mg/ml • 1 ml prefilled syringe (CE2265)
- REVOFIL Fine — Soft Touch Filler
- REVOFIL Plus — Sub Touch Filler
- REVOFIL Ultra — Deep Touch Filler
CROSS-LINKED FILLERS
Advantages of REVOFIL Fine, Plus & Ultra
REVOFIL’s cross-linked range is built on a unique 2X Filler technology. Each product contains a higher concentration of HA linked with a proprietary peptide complex, resulting in significantly increased stability of the HA gel. The strong inhibition of endogenous hyaluronidase extends the duration of the gel in the skin — delivering results that last twice as long as conventional fillers.
REVOFIL Fine
Soft Touch Filler — 30G ½ needle, superficial dermis. Ideal for tear troughs, fine lines, temporal region, upper cheeks, hollow cheeks, and lip lifting/augmentation.
REVOFIL Plus
Sub Touch Filler — 27G ½ needle, mid and deep dermis. Targets forehead, nose bridge, nasolabial folds, marionette lines, tear troughs, upper cheeks, jaw, chin, and mandibular region.
REVOFIL Ultra
Deep Touch Filler — 27G ½ needle, deep and subcutaneous dermis. Addresses forehead, nose bridge, nasolabial folds, marionette lines, cheeks, jaw, chin, and mandibular region.
Composition of REVOFIL Fine, Plus & Ultra
All three cross-linked REVOFIL fillers share the same core formulation: Sodium Hyaluronate Crosspolymer-2 at 23 mg/ml in a PBS base, enriched with two key bioactive peptides — Oligopeptide-72 (CG-Boostrin) and Oligopeptide-50 (CG-Glamerin). This consistent peptide-HA matrix ensures high elasticity, stable fluidity, and prolonged duration across all three products.
Sodium Hyaluronate Crosspolymer-2
23 mg/ml — the primary structural component providing volume, elasticity, and hydration in the dermal layer.
Oligopeptide-72 (CG-Boostrin)
A patented peptide that strongly inhibits hyaluronidase activity, significantly extending the longevity of the HA gel in skin.
Oligopeptide-50 (CG-Glamerin)
Supports skin firmness and structural integrity, complementing the cross-linked HA matrix for optimal aesthetic outcomes.
PBS Base
Phosphate-buffered saline carrier — biocompatible and pH-balanced to ensure safe, comfortable implantation in the dermal layer.
SCIENCE
Revolutionary Peptides: Rheological Properties *
REVOFIL Ultra, Plus, and Fine demonstrate high shear storage modulus (G’) and stable shear loss modulus (G”) in Dynamic Mechanical Analysis. These results confirm high elasticity, long duration, and stable fluidity across the entire product range.
Viscoelastic Performance
The log-log plot of elasticity (logG’) and fluidity (logG”) versus frequency demonstrates superior mechanical properties across the REVOFIL range. REVOFIL Ultra leads with the highest elasticity and fluidity.
Molecular Structure of Reticulated HA Gel *
REVOFIL’s unique gel architecture begins with cross-linked HA and peptide molecules that form cross-linked HA spheres, which then assemble into the final REVOFIL gel structure. Free HAs are connected to the peptide-mediated disulfide bond, while amide bond formation between free HA and cross-linked HA further reinforces the network.
Cross-linked HA and peptide
Cross-linked HA sphere
REVOFIL gel
Cross Linkage Bond
Primary structural bonds forming the HA polymer network.
Amide Bond
Formation between free HA and cross-linked HA for added reinforcement.
Peptide Disulfide Bond
Free HAs connected via peptide-mediated disulfide bonds for extended stability.
Clinical Test Data: Before & After **
One hundred seventy-two (172) patients were injected with REVOFIL Fine (30), REVOFIL Plus (86), and REVOFIL Ultra (56), aged 20–56. The affirmative results were reached by 99% of patients in the clinical study.
REVOFIL Fine — Lip Augmentation
Female, early 30’s. Significant increase in lip volume and smoothness visible at 6 months post-injection.
REVOFIL Plus — Nasolabial Folds (40’s)
Female, early 40’s. Marked reduction in nasolabial fold depth at 6 months post-injection.
.webp)
REVOFIL Plus — Nasolabial Folds (30’s)
Female, early 30’s. Further reduction in nasolabial fold depth confirmed at 6 months.
REVOFIL Ultra — Upper Cheeks
Female, early 40’s. Smoothing of upper cheek and periorbital area visible at 6 months.
REVOFIL Ultra — Nasolabial Folds (50’s)
Female, early 50’s. Significant bilateral reduction in nasolabial fold depth at 6 months.
Indication & Summary Table*
All three cross-linked REVOFIL fillers are injected into the mid-to-deep dermal layer for the treatment of subcutaneous tissue damage caused by chemical, physical, and traumatic effects — including facial wrinkles and nasolabial folds — and to restore the shape of the face.
| Specification | REVOFIL Fine | REVOFIL Plus | REVOFIL Ultra |
|---|---|---|---|
| HA Concentration | 23 mg/mL | 23 mg/mL | 23 mg/mL |
| Needle | 30G ½ | 27G ½ | 27G ½ |
| Injection Depth | Superficial dermis | Mid, Deep dermis | Deep, Subcutaneous dermis |
| Injection Areas | Tear troughs, fine lines, upper cheeks | Forehead, nose bridge, nasolabial folds | Cheeks, jaw, chin, mandibular region |
| Pack Size | 1 mL prefilled syringe | 1 mL prefilled syringe | 1 mL prefilled syringe |
Why Akumentis Healthcare
Akumentis Healthcare is committed to bringing the most innovative and scientifically validated aesthetic solutions to medical professionals. Through our collaboration with Caregen, we introduce the advanced REVOFIL dermal filler range to support modern aesthetic practices. Our partnership approach ensures that practitioners gain access to cutting-edge technologies supported by clinical guidance, educational resources, and ongoing training. REVOFIL represents our commitment to advancing aesthetic medicine through evidence-based innovation that enhances treatment outcomes and practice differentiation.
Quality Assurance
Every REVOFIL product follows rigorous quality standards and comprehensive testing protocols to ensure consistency, safety, and reliable performance across every batch.
Clinical Support
Our dedicated technical support team provides guidance on injection techniques, treatment planning assistance, and professional consultation for optimal results.
Professional Education
Training programs, educational resources, and hands-on workshops help practitioners confidently deliver safe and effective REVOFIL treatments.
Ready to Transform Your Practice?
Contact Akumentis Healthcare today to learn more about integrating REVOFIL into your aesthetic treatment portfolio. Our team is ready to provide product information, clinical support, and guidance to help deliver exceptional patient outcomes.
REVOFIL dermal fillers are intended for use by licensed medical professionals trained in aesthetic injection techniques. Results may vary depending on patient characteristics, injection technique, and treatment protocols.
*Data on file, as shared by Caregen team, and **Clinical studies done by Caregen
Request Product & Clinical Reference PDFs
Interested in detailed product information, clinical studies, efficacy reports, or reference documents?
Share your details and our team will connect with you with the relevant PDF documents accordingly.